Title Poseida Therapeutics Receives Orphan Drug Designation for PBCMAALLO1 Targeting Multiple Myeloma
On March 13, 2024, Poseida Therapeutics received Orphan Drug Designation from the FDA for their innovative treatment, P-BCMA-ALLO1, targeting Multiple ...
